Anti-Influenza Drug Avigan ® Tablet Meets Primary Endpoint in Phase III Clinical Trial in Japan for COVID-19 Patients

TOKYO— September 23, 2020 FUJIFILM Toyama Chemical Co., Ltd. (President: Junji Okada; hereinafter“FUJIFILM Toyama Chemical”) has announced today that primary endpoint has been met in phase III clinical trial of“Avigan...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials